LXQ-217 

LXQ-217 is an oral active SHP2 inhibitor with the IC₅₀ of 2.01 μM. LXQ-217 induces apoptosis and inhibits cell growth in vivo and in vitro^[1].

LXQ-217 (72 h) inhibits cell growth of A549, HCT116, HepG2 and MDA-MB-231 cells with the IC₅₀ values of 2.06, 3.88, 4.53, and 5.13 μM^[1].
LXQ-217 (2.5, 5, 10 μM, 7 days) decreases the clonogenic number and formation rate of A549 cells^[1].
LXQ-217 (1.25, 2.5 μM, 24 h) inhibits the migration of A549 cells^[1].
LXQ-217 (2.5, 5, 10 μM, 3 h) increases in the levels cleaved-parp (C-parp), cleaved-caspase9 (C-cas9) and cleaved-caspase3 (C-cas3) in A549 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

LXQ-217 (50, 100mg/kg; Oral administration for 14 days) inhibites the growth of A549 cell xenograft model constructed based on BALB/c-nude mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

576.23

C₂₄H₂₀Br₂N₂O₅

2524718-79-2

CCOC(C=C1)=CC=C1OC2=CC=C(C3=NN(C=O)C(C4=C(Br)C(Br)=C(O)C(O)=C4)C3)C=C2

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Sun H, et al. Small Molecule SHP2 Inhibitor LXQ-217 affects Lung Cancer Cell Proliferation in Vitro and in Vivo. Chem Biodivers. Published online February 20, 2024.  [Content Brief]